LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 581

Search options

  1. Article ; Online: PROMISE of low-cost immunosuppressants for myasthenia gravis.

    Ramdas, Sithara / Palace, Jacqueline

    The Lancet. Neurology

    2024  Volume 23, Issue 3, Page(s) 223–225

    MeSH term(s) Humans ; Immunosuppressive Agents/therapeutic use ; Myasthenia Gravis/drug therapy
    Chemical Substances Immunosuppressive Agents
    Language English
    Publishing date 2024-01-24
    Publishing country England
    Document type Journal Article
    ZDB-ID 2081241-3
    ISSN 1474-4465 ; 1474-4422
    ISSN (online) 1474-4465
    ISSN 1474-4422
    DOI 10.1016/S1474-4422(24)00034-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5955: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: It's not multiple sclerosis, what is it?!

    Huda, Saif / Palace, Jacqueline

    Practical neurology

    2023  Volume 23, Issue 4, Page(s) 270–272

    MeSH term(s) Humans ; Sclerosis ; Multiple Sclerosis/diagnostic imaging
    Language English
    Publishing date 2023-04-26
    Publishing country England
    Document type Editorial
    ZDB-ID 2170881-2
    ISSN 1474-7766 ; 1474-7758
    ISSN (online) 1474-7766
    ISSN 1474-7758
    DOI 10.1136/pn-2022-003677
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6001: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Book ; Online: Fast Facts : Recognizing Refractory Myasthenia Gravis

    Silvestri, Nicholas J. / Palace, Jacqueline A.

    (Fast Facts)

    2018  

    Abstract: An in-depth look at a rare disease Myasthenia gravis (MG) is a rare autoimmune disorder of the neuromuscular junction, characterized by muscle fatigability. Patients often initially present with ocular symptoms, but in most cases the disease spreads ... ...

    Author's details Nicholas J. Silvestri, Jacqueline A. Palace
    Series title Fast Facts
    Abstract An in-depth look at a rare disease Myasthenia gravis (MG) is a rare autoimmune disorder of the neuromuscular junction, characterized by muscle fatigability. Patients often initially present with ocular symptoms, but in most cases the disease spreads beyond the eye muscles to more generalized involvement of bulbar, facial, neck, proximal limb and respiratory muscles. With adequate treatment, most patients with MG are able to live productive lives with few or no symptoms, but a distinct subset of patients do not respond to conventional treatment. With new treatment options on the horizon, it is important that these patients are identified. 'Fast Facts: Recognizing Refractory Myasthenia Gravis' takes an in-depth look at: • the immune-mediated nature of MG • classification of MG by disease type and severity, and antibody status • clinical presentation and diagnostic work-up • conventional management options • how patients with treatment-refractory MG present • the assessment tools that can be used to identify non-responders. This informative resource will be of value to neurologists, neurology trainees and ophthalmologists caring for patients with this rare disease, as well as patients with MG who wish to have a deeper dialog with their doctor or patient group. Contents: • Definition and epidemiology • Pathophysiology and classification • Diagnosis and management: an overview • Assessment of disease severity and treatment response
    Keywords Myasthenia gravis/Diagnosis
    Subject code 616.7442
    Language English
    Dates of publication 2018-2018
    Size 1 online resource (49 pages) :, color illustrations.
    Publisher Health Press
    Publishing place Oxford, England
    Document type Book ; Online
    ISBN 1-910797-55-3 ; 1-910797-54-5 ; 1-910797-53-7 ; 978-1-910797-55-6 ; 978-1-910797-54-9 ; 978-1-910797-53-2
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  4. Article ; Online: Congenital myasthenic syndromes.

    Henehan, Leighann / Beeson, David / Palace, Jacqueline

    Practical neurology

    2024  

    Language English
    Publishing date 2024-04-17
    Publishing country England
    Document type Editorial
    ZDB-ID 2170881-2
    ISSN 1474-7766 ; 1474-7758
    ISSN (online) 1474-7766
    ISSN 1474-7758
    DOI 10.1136/pn-2024-004098
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6001: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Should We test for IgG Antibodies Against MOG in Both Serum and CSF in Patients With Suspected MOGAD?

    Kim, Ho Jin / Palace, Jacqueline

    Neurology

    2022  Volume 100, Issue 11, Page(s) 497–498

    MeSH term(s) Humans ; Immunoglobulin G ; Neuromyelitis Optica ; Myelin-Oligodendrocyte Glycoprotein ; Autoantibodies ; Aquaporin 4
    Chemical Substances Immunoglobulin G ; Myelin-Oligodendrocyte Glycoprotein ; Autoantibodies ; Aquaporin 4
    Language English
    Publishing date 2022-12-16
    Publishing country United States
    Document type Editorial ; Research Support, Non-U.S. Gov't ; Comment
    ZDB-ID 207147-2
    ISSN 1526-632X ; 0028-3878
    ISSN (online) 1526-632X
    ISSN 0028-3878
    DOI 10.1212/WNL.0000000000206805
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ui II Zs.153: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MG 18: Show issues
    Zs.MO 374: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Double-negative neuromyelitis optica spectrum disorder.

    Wu, Yan / Geraldes, Ruth / Juryńczyk, Maciej / Palace, Jacqueline

    Multiple sclerosis (Houndmills, Basingstoke, England)

    2023  Volume 29, Issue 11-12, Page(s) 1353–1362

    Abstract: Most patients with neuromyelitis optica spectrum disorders (NMOSD) test positive for aquaporin-4 antibody (AQP4-IgG) or myelin oligodendrocyte glycoprotein antibodies (MOG-IgG). Those who are negative are termed double-negative (DN) NMOSD and may ... ...

    Abstract Most patients with neuromyelitis optica spectrum disorders (NMOSD) test positive for aquaporin-4 antibody (AQP4-IgG) or myelin oligodendrocyte glycoprotein antibodies (MOG-IgG). Those who are negative are termed double-negative (DN) NMOSD and may constitute a diagnostic and therapeutic challenge. DN NMOSD is a syndrome rather than a single disease, ranging from a (postinfectious) monophasic illness to a more chronic syndrome that can be indistinguishable from AQP4-IgG+ NMOSD or develop into other mimics such as multiple sclerosis. Thus, underlying disease mechanisms are likely to be heterogeneous. This topical review aims to (1) reappraise antibody-negative NMOSD definition as it has changed over time with the development of the AQP4 and MOG-IgG assays; (2) outline clinical characteristics and the pathophysiological nature of this rare entity by contrasting its differences and similarities with antibody-positive NMOSD; (3) summarize laboratory characteristics and magnetic resonance imaging findings of DN NMOSD; and (4) discuss the current treatment for DN NMOSD.
    MeSH term(s) Humans ; Neuromyelitis Optica/diagnostic imaging ; Neuromyelitis Optica/therapy ; Aquaporin 4 ; Myelin-Oligodendrocyte Glycoprotein ; Immunoglobulin G ; Multiple Sclerosis ; Autoantibodies
    Chemical Substances Aquaporin 4 ; Myelin-Oligodendrocyte Glycoprotein ; Immunoglobulin G ; Autoantibodies
    Language English
    Publishing date 2023-09-23
    Publishing country England
    Document type Journal Article ; Review ; Research Support, Non-U.S. Gov't
    ZDB-ID 1290669-4
    ISSN 1477-0970 ; 1352-4585
    ISSN (online) 1477-0970
    ISSN 1352-4585
    DOI 10.1177/13524585231199819
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4428: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Effects of immunotherapies and clinical outcomes in neurosarcoidosis: a retrospective cohort study.

    Arun, Tarunya / Palace, Jacqueline

    Journal of neurology

    2021  Volume 268, Issue 7, Page(s) 2466–2472

    Abstract: Introduction: Neurosarcoidosis is associated with a significant degree of morbidity and mortality and its treatments are varied and complex. There is a paucity of information in current literature on patterns of treatment and long term outcomes. This ... ...

    Abstract Introduction: Neurosarcoidosis is associated with a significant degree of morbidity and mortality and its treatments are varied and complex. There is a paucity of information in current literature on patterns of treatment and long term outcomes. This study aimed to evaluate the clinical outcomes and responses to immunosuppressive therapy in a large cohort of neurosarcoidosis patients .
    Methods: We enrolled 80 patients with a diagnosis of neurosarcoidosis. Prescription patterns and clinical outcomes before and after treatment and differences between the treatment groups were compared using Kruskal-Wallis and Mann-Witney U tests.
    Results: Patients with cranial mononeuropathy other than optic neuropathy were more likely to be treated with steroids alone whereas patients with other presentations were likely to require second and third level treatments. These included azathioprine, methotrexate, mycophenolate, infliximab, and cyclophosphamide often used in combination. Prednisolone alone at onset failed in 67% of patients but appeared most effective in those with isolated facial nerve palsy. Patients treated with prednisolone plus a standard immunosuppression first line generally did well except for those with brain parenchymal disease and /or hydrocephalus who responded better to the addition of infliximab, or cyclophosphamide. Triple therapy with prednisolone + azathioprine + infliximab was associated with significantly greater improvement on the Modified Rankin Scale than prednisolone alone whether used first line (p = 0.001 corrected) or subsequently (p = 0.021 corrected). Overall favourable outcomes in the form of improvement of MRS were reported in 87%, CONCLUSIONS: Our results provides evidence that early immunosuppressive treatments, with azathioprine, methotrexate and infliximab could effectively improve clinical outcomes in many patients with neurosarcoidosis.
    MeSH term(s) Central Nervous System Diseases/drug therapy ; Humans ; Immunosuppressive Agents/therapeutic use ; Immunotherapy ; Retrospective Studies ; Sarcoidosis/drug therapy
    Chemical Substances Immunosuppressive Agents
    Language English
    Publishing date 2021-01-30
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 187050-6
    ISSN 1432-1459 ; 0340-5354 ; 0012-1037 ; 0939-1517 ; 1619-800X
    ISSN (online) 1432-1459
    ISSN 0340-5354 ; 0012-1037 ; 0939-1517 ; 1619-800X
    DOI 10.1007/s00415-021-10421-z
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ui II Zs.40: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: A systematic literature review to examine the considerations around pregnancy in women of child-bearing age with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) or aquaporin 4 neuromyelitis optica spectrum disorder (AQP4+ NMOSD).

    Leite, M Isabel / Panahloo, Zoya / Harrison, Niall / Palace, Jacqueline

    Multiple sclerosis and related disorders

    2023  Volume 75, Page(s) 104760

    Abstract: Background: Aquaporin-4 antibody positive (AQP4+) neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) are rare autoimmune diseases with overlapping phenotypes. Understanding their ... ...

    Abstract Background: Aquaporin-4 antibody positive (AQP4+) neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) are rare autoimmune diseases with overlapping phenotypes. Understanding their clinical manifestation prior to, during and after pregnancy may influence the management of women of child-bearing age (WOCBA) with these diseases.
    Methods: This systematic review identified relevant MEDLINE-indexed publications dated between 01 January 2011 and 01 November 2021, and congress materials from key conferences between 01 January 2019 and 01 November 2021. These were manually assessed for relevance to AQP4+ NMOSD and/or MOGAD in WOCBA, with selected data extracted and considered.
    Results: In total, 107 articles were retrieved and reviewed for relevancy, including 65 clinical studies. Limited evidence was found regarding a conclusive impact of either disease on female fertility, sexual function or menarche, and impact on maternal outcomes requires further investigation in both conditions to establish risk for pre-eclampsia, gestational diabetes and other complications relative to the general population. Collated data for pregnancy outcomes show clear risks in AQP4+ NMOSD to healthy delivery and a rise in annualised relapse rate postpartum that may require adaptation of treatment regimens. Disease activity appears to be attenuated during pregnancy in MOGAD patients with an increased risk of relapse during the postpartum months, but strong conclusions cannot be made due to a paucity of available data.
    Conclusions: This review brings together the literature on AQP4+ NMOSD and MOGAD in WOCBA. The potential impact of pregnancy and the postpartum period on disease activity suggest a proactive management strategy early on may improve maternal and infant outcomes, but more clinical data are needed, particularly for MOGAD.
    MeSH term(s) Female ; Humans ; Pregnancy ; Aquaporin 4 ; Neuromyelitis Optica/drug therapy ; Myelin-Oligodendrocyte Glycoprotein ; Autoantibodies ; Autoimmune Diseases
    Chemical Substances Aquaporin 4 ; Myelin-Oligodendrocyte Glycoprotein ; Autoantibodies
    Language English
    Publishing date 2023-05-11
    Publishing country Netherlands
    Document type Systematic Review ; Journal Article ; Review
    ZDB-ID 2645330-7
    ISSN 2211-0356 ; 2211-0348
    ISSN (online) 2211-0356
    ISSN 2211-0348
    DOI 10.1016/j.msard.2023.104760
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: MOG antibody-associated disease after vaccination with ChAdOx1 nCoV-19.

    Francis, Anna / Palace, Jacqueline / Fugger, Lars

    The Lancet. Neurology

    2022  Volume 21, Issue 3, Page(s) 217–218

    MeSH term(s) COVID-19 ; ChAdOx1 nCoV-19 ; Humans ; Vaccination
    Chemical Substances ChAdOx1 nCoV-19 (B5S3K2V0G8)
    Language English
    Publishing date 2022-02-19
    Publishing country England
    Document type Letter
    ZDB-ID 2081241-3
    ISSN 1474-4465 ; 1474-4422
    ISSN (online) 1474-4465
    ISSN 1474-4422
    DOI 10.1016/S1474-4422(22)00043-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5955: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Placebo studies should not be undertaken in NMO--Yes.

    Palace, Jacqueline

    Multiple sclerosis (Houndmills, Basingstoke, England)

    2015  Volume 21, Issue 6, Page(s) 689–691

    MeSH term(s) Clinical Trials as Topic/standards ; Humans ; Neuromyelitis Optica/drug therapy ; Placebos/standards ; Research Design/standards
    Chemical Substances Placebos
    Language English
    Publishing date 2015-05
    Publishing country England
    Document type Comment ; Journal Article
    ZDB-ID 1290669-4
    ISSN 1477-0970 ; 1352-4585
    ISSN (online) 1477-0970
    ISSN 1352-4585
    DOI 10.1177/1352458515579446
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4428: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top